Menu

Blog

Apr 22, 2020

Tel Aviv University scientist awarded US patent for novel coronavirus vaccine design

Posted by in category: biotech/medical

This is pretty cool:

The vaccine targets the novel coronavirus’s Achilles’ heel, its Receptor Binding Motif (RBM), a critical structure that enables the virus to bind to and infect a target cell. According to Prof. Gershoni, the vaccine would reconstruct the coronavirus’s RBM, a tiny feature of its “spike” protein. Though the virus uses many different proteins to replicate and invade cells, the “spike” protein is the major surface protein that it uses to bind to a receptor — another protein that acts like a doorway into a human cell. After the spike protein binds to the human cell receptor, the viral membrane fuses with the human cell membrane, allowing the genome of the virus to enter human cells and begin infection.


Tel Aviv University’s Professor Jonathan Gershoni has been awarded a US patent for a novel coronavirus vaccine design.

Leave a reply